Details

Autor(en) / Beteiligte

• Ounchanum, Pradthana
• Aurpibul, Linda
• Teeraananchai, Sirinya
• Lumbiganon, Pagakrong
• Songtaweesin, Wipaporn Natalie
• Sudjaritruk, Tavitiya
• Chokephaibulkit, Kulkanya
• Rungmaitree, Supattra
• Kosalaraksa, Pope
• Suwanlerk, Tulathip
• Ross, Jeremy L
• Sohn, Annette H
• Puthanakit, Thanyawee

Titel

High mortality in adolescents and young adults with perinatally-acquired HIV in Thailand during the transition to adulthood

Ist Teil von

• AIDS care, 2024-03, p.1-10

Ort / Verlag

England

Erscheinungsjahr

2024

Link zum Volltext

Beschreibungen/Notizen

• Transitioning from pediatric to adult care remains a challenge for adolescents and young adults with perinatally-acquired HIV (AYA-PHIV). We assessed treatment outcomes and mortality among Thai AYA-PHIV. The study included AYA-PHIV who reached age 18-24 years who started antiretroviral treatment during childhood at five pediatric HIV clinics across Thailand. From November 2020-July 2021, data were gathered from a cohort database, medical records, and the Thai National AIDS Program. Of 811 eligible AYA-PHIV, 93% were alive; median age 22.3 years (IQR 20.6-23.7), treatment duration 16.1 years (IQR 13.4-18.0). Current HIV care was provided in adults (71%) and pediatric clinics (29%). Treatment regimens included non-nucleoside reverse transcriptase inhibitors (55%), protease inhibitors (36%), and integrase inhibitors (8%); 78% had HIV RNA <200 copies/ml. Of the 7.0% who died, median age at death was 20.8 years (IQR 20.6-22.1); 88% were AIDS-related death. Mortality after age 18 was 1.76 per 100-person years (95% confidence interval 1.36-2.28). Those with CD4 <200 cell/mm at age 15 had higher risk of mortality (adjusted hazard ratio 6.16, 95% CI 2.37-16.02). In conclusion, the high mortality among Thai AYA-PHIV indicated the need for better systems to support AYA-PHIV during the transition to adulthood.